

FITC Annexin V

Catalog# / Size	640905 / 25 tests 640906 / 100 tests 640945 / 300 tests
Regulatory Status	RUO
Other Names	Annexin A5
Description	Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat. No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details

Verified Reactivity	All mammalian species
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation	The purified protein was conjugated with FITC under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm)
Application Notes	<p>Annexin V Staining</p> <ol style="list-style-type: none"> 1. Wash cells twice with cold BioLegend cell staining buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x10⁶ cells/mL. 2. Transfer 100 µL of cell suspension in 5 ml test tube. 3. Add 5 µL of FITC Annexin V. 4. Add 10 µL of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404). 5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark. 6. Add 400 µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry. <p>For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.</p>
Application References	<ol style="list-style-type: none"> 1. Koopman G, et al. 1994. <i>Blood</i> 84:1415. 2. Vermes I, et al. 1995. <i>J. Immunol. Methods</i> 184:39. 3. Dachary-Prigent J, et al. 1993. <i>Blood</i> 81:2554. 4. Sekine C, et al. 2009. <i>Int Immunol.</i> PubMed 5. Grujic M, et al. 2010. <i>J. Immunol.</i> 185:1730. PubMed 6. Mulik RS, et al. 2010. <i>Int J Pharm.</i> 398:190. PubMed 7. Gupta A, et al. 2011. <i>Leuk Res.</i> 35:1498. PubMed
(PubMed link indicates BioLegend citation)	

8. Speth C, et al. 2013. *J Infect Dis.* 207:823. [PubMed](#)
9. Wang Q, et al. 2013. *Genes Dev.* 27:615. [PubMed](#)
10. Gill K, et al. 2013. *Biochem Biophys Acta.* 830:2763. [PubMed](#)
11. Juel HB, et al. 2013. *PLoS One.* 8:64619. [PubMed](#)
12. Hellmann J, et al. 2013. *J. Immunol.* 191:1383. [PubMed](#)
13. Sequier S, et al. 2013. *PLoS One.* 8:70937. [PubMed](#)
14. Galski H, et al. 2013. *Biochem Pharmacol.* 86:584. [PubMed](#)
15. Chen YL, et al. 2013. *J Exp Med.* [PubMed](#)
16. Lin WH, et al. 2014. *PLoS One.* 9:83160. [PubMed](#)
17. Salge-Bartles U, 2014. *Thromb res.* 133:244. [PubMed](#)
18. Zhang X, et al. 2014. *Acta Biochim Biophys Sin.* 46:261. [PubMed](#)
19. Intermann J, et al. 2014. *Cell Signal.* 26:1567. [PubMed](#)
20. de Vires M, 2014. *Am J Physiol Lung Cell Mol Physiol.* 307:240. [PubMed](#)
21. M Parrula MC, et al. 2014. *Virus Res.* 189:206. [PubMed](#)
22. Passaro C, et al. 2014. *Mol Oncol.* 9:78. [PubMed](#)
23. Tsou WI, et al. 2014. *J Biol Chem.* 289:25750. [PubMed](#)
24. Awojoodu AO, et al. 2014. *Blood.* 124:1941. [PubMed](#)
25. Xiong R, et al. 2014. *Toxicol Appl Pharmacol.* 280:285. [PubMed](#)
26. Liu J, et al. 2015. *J Mol Cell Cardiol.* 80:10. [PubMed](#)

Product Citations

1. Derudder E, et al. 2016. *Proc Natl Acad Sci U S A.* 113: 5065-5070. [PubMed](#)
2. Yao Z, et al. 2018. *J Virol.* 92:00:00. [PubMed](#)
3. Uriostegui-Arcos M, et al. 2020. *Open Biol.* 10:200050. [PubMed](#)
4. Zhang T, et al. 2022. *EBioMedicine.* 77:103872. [PubMed](#)
5. Dhoonmoon A, et al. 2022. *Nat Commun.* 13:5063. [PubMed](#)
6. Zelenka T, et al. 2022. *Nat Commun.* 13:6954. [PubMed](#)
7. Kim EH, et al. 2020. *Elife.* 9:00. [PubMed](#)
8. Kitayama J, et al. 2016. *PLoS One.* 11: 0154542. [PubMed](#)
9. Gedye C, et al. 2016. *Sci Rep.* 6: 25220. [PubMed](#)
10. Carlsson J, et al. 2015. *PLoS One.* 10: 0143741. [PubMed](#)
11. Bouhaddou M, et al. 2018. *PLoS Comput Biol.* 14:e1005985. [PubMed](#)
12. Espinosa-Cueto P, et al. 2017. *PLoS One.* 10.1371/journal.pone.0182126. [PubMed](#)
13. Dowling CM, et al. 2021. *Sci Adv.* 7: . [PubMed](#)
14. Lin YN, et al. 2022. *Oncoimmunology.* 11:2027136. [PubMed](#)
15. Gupta A, et al. 2011. *Leuk Res.* 35:1498. [PubMed](#)
16. Fujii T, et al. 2015. *Proc Natl Acad Sci U S A.* 112: 12800 - 12805. [PubMed](#)
17. Cardoso B, et al. 2015. *PLoS One.* 10: 0143897. [PubMed](#)
18. Alcon C, et al. 2020. *Cell Death Dis.* 0.898611111. [PubMed](#)
19. Yamauchi T et al. 2018. *Cancer cell.* 33(3):386-400 . [PubMed](#)
20. Feng W, et al. 2017. *Nat Commun.* 0.697916667. [PubMed](#)
21. Jones PD, et al. 2018. *Arterioscler Thromb Vasc Biol.* 38:1711. [PubMed](#)
22. Figueiredo T, et al. 2020. *Mol Psychiatry.* . [PubMed](#)
23. Lopes-Coelho F, et al. 2021. *Front Oncol.* 11:656229. [PubMed](#)
24. Wang Q, et al. 2022. *Nat Commun.* 13:3022. [PubMed](#)
25. Olelewe C, et al. 2022. *iScience.* 25:104340. [PubMed](#)
26. Ramalingam P, et al. 2020. *J Exp Med.* 217:00:00. [PubMed](#)
27. Bowen ME, et al. 2019. *Dev Cell.* 50:212. [PubMed](#)
28. Sales-Dias J, et al. 2019. *PLoS One.* 14:e0217002. [PubMed](#)
29. Santos LC, et al. 2019. *Nat Commun.* 1.328472222. [PubMed](#)
30. Lim JA, et al. 2018. *BMC Cancer.* 0.860416667. [PubMed](#)
31. Venter C, et al. 2017. *Cell Physiol Biochem.* 43:1288. [PubMed](#)
32. Kim Y, et al. 2020. *J Neurochem.* 155:177. [PubMed](#)
33. Hassan MIA, et al. 2021. *Comput Struct Biotechnol J.* 19:880. [PubMed](#)
34. Soprano M, et al. 2016. *PLoS One.* 11: 0155970. [PubMed](#)
35. Macpherson L, et al. 2020. *Nature.* 577:266. [PubMed](#)
36. Karavasili C, et al. 2017. *International Journal of Pharmaceutics.* 10.1016/j.ijpharm.2017.05.061. [PubMed](#)
37. Thompson PJ et al. 2019. *Cell metabolism.* 29(5):1045-1060 . [PubMed](#)
38. Noguchi F, et al. 2017. *Mol Cancer Ther.* 1.316666667. [PubMed](#)
39. Kumar S, et al. 2018. *Cancers (Basel).* 0.724305556. [PubMed](#)
40. Fortin J, et al. 2020. *Cancer Cell.* 37:308. [PubMed](#)
41. Vereertbrugghen A, et al. 2021. *Front Oncol.* 11:598319. [PubMed](#)
42. Sun V, et al. 2021. *Front Immunol.* 12:716661. [PubMed](#)
43. Coray M, et al. 2022. *Int J Mol Sci.* 23: . [PubMed](#)
44. He C, et al. 2021. *Oncoimmunology.* 1897295:10. [PubMed](#)
45. Pfalzgraff A, et al. 2016. *Sci Rep.* 6:31577. [PubMed](#)
46. O'Neill K, et al. 2016. *Genes Dev.* 30: 973-988. [PubMed](#)
47. Liu J, et al. 2015. *J Mol Cell Cardiol.* 80:10. [PubMed](#)
48. Vries M, et al. 2014. *Am J Physiol Lung Cell Mol Physiol.* 307:240. [PubMed](#)
49. Chen MS, et al. 2019. *Mol Cancer Res.* 17:697. [PubMed](#)
50. Ni F, et al. 2019. *Cell Stem Cell.* 24:608. [PubMed](#)
51. Ning X, et al. 2019. *Mol Cell.* 74:19. [PubMed](#)
52. Greenblatt SM, et al. 2018. *Cancer Cell.* 33:1111. [PubMed](#)
53. Naqvi N, et al. 2017. *Sci Rep.* 10.1038/s41598-017-12753-1. [PubMed](#)
54. Wang M, et al. 2017. *Biochemical and Biophysical Research Communications.* 10.1016/j.bbrc.2017.05.097. [PubMed](#)
55. Beeravolu N, McKee C, Chaudhry G 2017. *J App Toxicol.* 10.1002/jat.3469. [PubMed](#)
56. Kim OV, et al. 2022. *iScience.* 25:104654. [PubMed](#)

57. Shahzadi SK, *et al.* 2022. Clin Sci (Lond). 136:181. [PubMed](#)
58. Kolbrink B, *et al.* 2022. Biochem J. 479:259. [PubMed](#)
59. Parrula M, *et al.* 2014. Virus Res. 189:206. [PubMed](#)
60. Brigger D, *et al.* 2015. Cell Death Dis. 6: e1861. [PubMed](#)
61. Zhang J, *et al.* 2016. Cell Death Dis. 7:e2266. [PubMed](#)
62. Wang D, *et al.* 2016. J Cell Sci. 129: 2261 - 2272. [PubMed](#)
63. Uchtenhagen H, *et al.* 2016. Nat Commun. 7:12614. [PubMed](#)
64. Geiger R, *et al.* 2016. Cell. 167:829-842. [PubMed](#)
65. Esteghamat F, *et al.* 2019. Nat Genet. 51:1233. [PubMed](#)
66. Blümel E, *et al.* 2020. Oncoimmunology. 9:1751561. [PubMed](#)
67. Sekine C, *et al.* 2009. Int Immunol. 1.079861111. [PubMed](#)
68. Kinsella S, *et al.* 2021. Cell Rep. 37:109789. [PubMed](#)
69. O'Connor MJ, *et al.* 2021. Oncogene. 40:4872. [PubMed](#)
70. Madala HR, *et al.* 2020. Cancer Res. 3492:80. [PubMed](#)
71. Clements KE, *et al.* 2020. Nat Commun. 4.706944444. [PubMed](#)
72. Raouzan M, *et al.* 2017. PLoS One. 12:e0174107. [PubMed](#)
73. Liu Y, *et al.* 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. [PubMed](#)
74. Chiani M, *et al.* 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. [PubMed](#)
75. Yang L, *et al.* 2021. Cell Death Differ. 28:2616. [PubMed](#)
76. Martín Monreal MT, *et al.* 2021. Front Immunol. 12:716250. [PubMed](#)
77. Schmitz RL, *et al.* 2021. Cells. 10:. [PubMed](#)
78. Babaei A, *et al.* 2021. Adv Pharm Bull. 11:361. [PubMed](#)
79. Salge-Bartels U, *et al.* 2014. Thromb Res. 133:244. [PubMed](#)
80. Passaro C, *et al.* 2014. Mol Oncol. 9:78. [PubMed](#)
81. Ligtenberg M, *et al.* 2016. J Immunol. 196: 759 - 766. [PubMed](#)
82. Hrdinka M, *et al.* 2016. PLoS One. 11: 0162863. [PubMed](#)
83. Herold N, *et al.* 2017. Nat Med. 23:256-263. [PubMed](#)
84. Xie S, *et al.* 2021. Sci Rep. 0.660416667. [PubMed](#)
85. Müller I, *et al.* 2020. Mol Cell. 970:77. [PubMed](#)
86. Kamiyama N, *et al.* 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. [PubMed](#)
87. Montero-Herradón S, *et al.* 2017. Organogenesis. 0.675. [PubMed](#)
88. Nunes SC, *et al.* 2018. Sci Rep. 6.939583333. [PubMed](#)
89. Sharif T, *et al.* 2018. Autophagy. 1.101388889. [PubMed](#)
90. Eichelmann AK, *et al.* 2018. Sci Rep. 8:17553. [PubMed](#)
91. Blümel E, *et al.* 2019. Oncoimmunology. 8:e1641387. [PubMed](#)
92. Morimoto A, *et al.* 2021. Nat Commun. 12:2136. [PubMed](#)
93. Norkin M, *et al.* 2021. Cell Rep. 35:109026. [PubMed](#)
94. Krauss PL, *et al.* 2021. Front Immunol. 12:730672. [PubMed](#)
95. Zhu Y, *et al.* 2022. Clin Transl Med. 12:e887. [PubMed](#)
96. Khatib JB, *et al.* 2022. Oncotarget. 13:1078. [PubMed](#)
97. Yoon Y, *et al.* 2016. Stem Cell Reports. 7:840-853. [PubMed](#)
98. Chheda Z, *et al.* 2016. J Immunol. 197: 2016 - 2026. [PubMed](#)
99. Slone E, *et al.* 2015. J Leukoc Biol. 98: 791 - 804. [PubMed](#)
100. Séguier S, *et al.* 2013. PLoS One. 8:70937. [PubMed](#)
101. Liu H, *et al.* 2020. Cell Death Dis. 0.767361111. [PubMed](#)
102. Zervou S, *et al.* 2017. PLoS One.. 10.1371/journal.pone.0182994. [PubMed](#)
103. Ishidome T *et al.* 2017. EBioMedicine. 22:89-99 . [PubMed](#)
104. Matsuda K, *et al.* 2021. Cell Rep Methods. 1:100122. [PubMed](#)
105. Vanoli F, *et al.* 2021. Oncogene. 40:5095. [PubMed](#)
106. Liu H, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
107. Smith CM, *et al.* 2021. Biochem J. 478:3331. [PubMed](#)
108. Li Y, *et al.* 2021. Sci Transl Med. 13:. [PubMed](#)
109. Meyer N, *et al.* 2021. J Clin Med. 10:. [PubMed](#)
110. Wang Q, *et al.* 2013. Genes Dev. 27:615. [PubMed](#)
111. Douguet L, *et al.* 2016. PLoS One. 11:e0166164. [PubMed](#)
112. Toutouchian J, *et al.* 2016. Mol Pharmacol. 91(1):1-13. [PubMed](#)
113. Pajarillo E, *et al.* 2020. J Biol Chem. 295:3040. [PubMed](#)
114. Litzemberger UM, *et al.* 2017. Genome Biol. 18:15. [PubMed](#)
115. Rajavel T, *et al.* 2017. Sci Rep. 2.665277778. [PubMed](#)
116. Grujic M, *et al.* 2010. J Immunol. 185:1730. [PubMed](#)
117. Gholamrezaei M, *et al.* 2021. Iran J Parasitol. 15:475. [PubMed](#)
118. Meyer N, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
119. Kolbrink B, *et al.* 2022. Cell Mol Life Sci. 79:387. [PubMed](#)
120. Alsina-Sanchis E, *et al.* 2020. Mol Cancer Res. . [PubMed](#)
121. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. [PubMed](#)
122. Becker A, *et al.* 2016. Sci Rep. 6: 33847. [PubMed](#)
123. Kumai T, *et al.* 2015. Sci Rep. 5:16280. [PubMed](#)
124. Polak R, *et al.* 2015. Blood. 126: 2404 - 2414. [PubMed](#)
125. Matsumoto A, *et al.* 2019. J Extracell Vesicles. 9:1696517. [PubMed](#)
126. Pirali T, *et al.* 2017. ChemMedChem. 1.570833333. [PubMed](#)
127. Ishida M, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
128. Lee DH, *et al.* 2020. Circ Res. 127:1182. [PubMed](#)
129. Galski H, *et al.* 2013. Biochem Pharmacol. 86:584. [PubMed](#)
130. Tsou W, *et al.* 2014. J Biol Chem. 289:25750. [PubMed](#)
131. Dhoonmoon A, *et al.* 2020. Nucleic Acids Res. 48:7252. [PubMed](#)
132. Hafez A, *et al.* 2017. Oncogenesis. 10.1038/oncsis.2017.46. [PubMed](#)
133. Putheti P, *et al.* 2010. PLoS One. 5:e8706. [PubMed](#)
134. Nastasi C, *et al.* 2021. Sci Rep. 11:1458. [PubMed](#)
135. Molinar-Inglis O, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. [PubMed](#)

136. Erdogan M, *et al.* 2022. Chem Biodivers. 19:e202200659. [PubMed](#)
137. Cai Z, *et al.* 2020. Cell Rep. 31:107816. [PubMed](#)
138. Liu B, *et al.* 2016. J Biol Chem. 291: 23869 - 23881. [PubMed](#)
139. Lhuillier C, *et al.* 2015. J Biol Chem. 290: 16797 - 16811. [PubMed](#)
140. Passaro C, *et al.* 2013. Endocr Relat Cancer. 20:633. [PubMed](#)
141. Mulik R, *et al.* 2010. Int J Pharm. 398:190. [PubMed](#)
142. Speth C, *et al.* 2013. J Infect Dis. 207:823. [PubMed](#)
143. Gladow N, *et al.* 2020. PLoS One. 15:e0227734. [PubMed](#)
144. Lee HW, *et al.* 2018. Am J Physiol Renal Physiol. 314:F280. [PubMed](#)
145. Ki H, *et al.* 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. [PubMed](#)
146. Shadboorestan A, *et al.* 2022. Iran J Basic Med Sci. 25:506. [PubMed](#)
147. Huang Y, *et al.* 2022. Front Cell Dev Biol. 9:837777. [PubMed](#)
148. Babaei A, *et al.* 2020. Daru. 28:555. [PubMed](#)
149. King R, *et al.* 2021. Sci Adv. 7:eabj5293. [PubMed](#)
150. Lin W, *et al.* 2014. PLoS One. 9:83160. [PubMed](#)
151. Zhang X, *et al.* 2014. Acta Biochim Biophys Sin. 46:261. [PubMed](#)
152. CO L, *et al.* 2015. Nat Commun. 6: 7739. [PubMed](#)
153. Huang YL, *et al.* 2020. Elife. 9:00. [PubMed](#)
154. Schuler F, *et al.* 2017. Nat Commun. . 10.1038/s41467-017-01850-4. [PubMed](#)
155. Di Somma S, *et al.* 2019. Cancers (Basel). 1.70625. [PubMed](#)
156. Abu El Maaty MA, *et al.* 2021. Sci Adv. 7: . [PubMed](#)
157. Bahl S, *et al.* 2021. Cell Death Dis. 12:469. [PubMed](#)
158. Jackson LM, *et al.* 2021. Nucleic Acids Res. 49:12855. [PubMed](#)
159. Faria M, *et al.* 2017. PLoS One. 12(2):e0172689. [PubMed](#)
160. Jones P, *et al.* 2016. J Biol Chem. 291: 16318 - 16327. [PubMed](#)
161. Awojoodu A, *et al.* 2014. Blood. 124:1941. [PubMed](#)
162. Intemann J, *et al.* 2014. Cell Signal. 26:1567. [PubMed](#)
163. Labi V, *et al.* 2019. Genes Dev. 33:1673. [PubMed](#)
164. Fang P, *et al.* 2019. Commun Biol. 0.315972222. [PubMed](#)
165. Kumar S, *et al.* 2019. Int J Cancer. 146:1652. [PubMed](#)
166. Zhao CC, *et al.* 2018. Oncol Rep. 40:3392. [PubMed](#)
167. Schleicher EM, *et al.* 2018. Nucleic Acids Res. 46:8908. [PubMed](#)
168. Thomas A, *et al.* 2017. PLoS One.. 10.1371/journal.pone.0183542. [PubMed](#)
169. Tatangelo V, *et al.* 2022. Front Oncol. 12:877495. [PubMed](#)
170. Alcon C, *et al.* 2021. Cells. 10: . [PubMed](#)
171. Cao H, *et al.* 2021. Nat Commun. 12:1792. [PubMed](#)
172. Clements KE, *et al.* 2018. Nucleic Acids Res. 46:8898. [PubMed](#)
173. Bostanabad SY, *et al.* 2021. Sci Rep. 11:1539. [PubMed](#)
174. Monzen S, *et al.* 2022. Mol Clin Oncol. 16:19. [PubMed](#)
175. Konda P, *et al.* 2022. Am J Cancer Res. 12:210. [PubMed](#)
176. Wu J, *et al.* 2021. Adv Sci (Weinh). 8:e2101029. [PubMed](#)
177. Zhang Y, *et al.* 2021. Cell Death Dis. 0.563194444. [PubMed](#)
178. Kang JH, *et al.* 2020. Cell Death Dis. 0.803472222. [PubMed](#)
179. Dewdney B, *et al.* 2020. Sci Rep. 10:16769. [PubMed](#)
180. Simoni L, *et al.* 2020. Cell Rep. 33:108330. [PubMed](#)
181. Coutaz M, *et al.* 2016. Sci Rep. 6:39117. [PubMed](#)
182. Akane K, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. [PubMed](#)
183. Xiong R, *et al.* 2014. Toxicol Appl Pharmacol. 280:285. [PubMed](#)
184. Chen Y, *et al.* 2013. J Exp Med. 210:2515. [PubMed](#)
185. Mendès C, *et al.* 2019. Sci Rep. 9:14107. [PubMed](#)
186. Lopes-Coelho F, *et al.* 2017. Oncotarget. 8:82803. [PubMed](#)
187. Lu Y, *et al.* 2018. Cancer Cell. 33:1048. [PubMed](#)
188. Thanuthanakhun N, *et al.* 2017. PLoS One. . 10.1371/journal.pone.0187610. [PubMed](#)
189. Kuntz E, *et al.* 2017. Nat Med. 10.1038/nm.4399. [PubMed](#)
190. Tu Z, *et al.* 2022. Cell Rep. 40:111072. [PubMed](#)
191. Bensberg M, *et al.* 2021. Proc Natl Acad Sci U S A. 118: . [PubMed](#)
192. Paparella AS, *et al.* 2021. Nat Commun. 12:6285. [PubMed](#)
193. Huang YL, *et al.* 2021. iScience. 24:103168. [PubMed](#)
194. Bottardi S, *et al.* 2020. Exp Hematol. 68:88. [PubMed](#)
195. Siddhartha V, *et al.* 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. [PubMed](#)
196. He J, *et al.* 2017. FASEB J. 31:2893. [PubMed](#)
197. Lyu X, *et al.* 2019. BMC Genomics. 1.235416667. [PubMed](#)
198. Jing Y, *et al.* 2019. J Allergy Clin Immunol. 144:1377. [PubMed](#)
199. Quan M, *et al.* 2019. Oncol Rep. 41:3051. [PubMed](#)
200. Kasikara C, *et al.* 2021. J Clin Invest. 131: . [PubMed](#)
201. Ning N, *et al.* 2022. Theranostics. 12:5537. [PubMed](#)
202. Du Z, *et al.* 2020. J Allergy Clin Immunol. . [PubMed](#)
203. Pahari S, *et al.* 2020. Autophagy. 1.375694444. [PubMed](#)
204. Schleicher EM, *et al.* 2020. PLoS Genet. 16:e1009176. [PubMed](#)
205. Langsch S, *et al.* 2016. Cancer Res . 76: 4160 - 4169. [PubMed](#)
206. Xiong R, *et al.* 2015. Mol Pharmacol. 88: 1045 - 1054. [PubMed](#)
207. Hellmann J, *et al.* 2013. J Immunol. 191:1383. [PubMed](#)
208. Juel H, *et al.* 2013. PLoS One. 8:64619. [PubMed](#)
209. Gill K, *et al.* 2013. Biochim Biophys Acta. 1830:2763. [PubMed](#)
210. Young MM, *et al.* 2019. Cell Death Dis. 1.004861111. [PubMed](#)
211. Santos I, *et al.* 2019. Nutrients. 2.210416667. [PubMed](#)
212. Vancsik T, *et al.* 2019. Cancer Med. 3.313888889. [PubMed](#)
213. Zheng M, *et al.* 2019. Proc Natl Acad Sci U S A. 116:12422. [PubMed](#)
214. Zheng Q, *et al.* 2017. Mol Oncol. 10.1002/1878-0261.12056. [PubMed](#)

215. Wang Y, *et al.* 2022. *Front Cardiovasc Med.* 9:876087. [PubMed](#)
216. Shankman LS, *et al.* 2021. *Curr Biol.* 31:2469. [PubMed](#)



RRID AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience

Gene ID [308](#)

Product Data



Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend's anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587